Chakrani, Z., Patel, M., Mellgard, G., McCroskery, S., Saffran, N., Taylor, N., Liaw, B. C., Galsky, M., Oh, W., Tsao, C.-K., Ganta, T., & Patel, V. (2024). The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer, 22(6), 102227. https://doi.org/10.1016/j.clgc.2024.102227

Kirk, J. S., Wang, J., Long, M., Rosario, S., Tracz, A., Ji, Y., Kumar, R., Liu, X., Jamroze, A., Singh, P. K., Puzanov, I., Chatta, G., Cheng, Q., Huang, J., Wrana, J. L., Lovell, J., Yu, H., Liu, S., Shen, M. M., … Tang, D. G. (2024). Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Cell Stem Cell, 31(8), 1203-1221.e7. https://doi.org/10.1016/j.stem.2024.05.008

Mellgard, G., Saffran, N., Chakrani, Z., McCroskery, S., Taylor, N., Patel, M., Liaw, B., Galsky, M., Oh, W., Tsao, C.-K., & Patel, V. (2024). Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal of Clinical Oncology, 47(10), 459–464. https://doi.org/10.1097/coc.0000000000001115

Chakrani, Z., Mellgard, G., Saffran, N., McCroskery, S., Taylor, N., Patel, M., Liaw, B., Galsky, M., Oh, W. K., Tsao, C.-K., & Patel, V. G. (2024). Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal of Clinical Oncology, 47(6), 271–278. https://doi.org/10.1097/coc.0000000000001087

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Madan, R. A., Bilusic, M., Stein, M. N., Donahue, R. N., Arlen, P. M., Karzai, F., Plimack, E., Wong, Y.-N., Geynisman, D. M., Zibelman, M., Mayer, T., Strauss, J., Chen, G., Rauckhorst, M., McMahon, S., Couvillon, A., Steinberg, S., Figg, W. D., Dahut, W. L., … Gulley, J. L. (2023). Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The Oncologist, 28(7), 642-e561. https://doi.org/10.1093/oncolo/oyad058

Morris, M. J., Heller, G., Hillman, D. W., Bobek, O., Ryan, C., Antonarakis, E. S., Bryce, A. H., Hahn, O., Beltran, H., Armstrong, A. J., Schwartz, L., Lewis, L. D., Beumer, J. H., Langevin, B., McGary, E. C., Mehan, P. T., Goldkorn, A., Roth, B. J., Xiao, H., … Small, E. J. (2023). Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology, 41(18), 3352–3362. https://doi.org/10.1200/jco.22.02394

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., Loffredo, J., Bandyopadhyay, N., Xie, H., & Hansen, A. R. (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 21(3), 366–375. https://doi.org/10.1016/j.clgc.2023.02.010

Guo, C., Figueiredo, I., Gurel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J., Bogdan, D., Gallagher, L., Sharp, A., Fenor de la Maza, M. D., Rescigno, P., Westaby, D., Chandran, K., Riisnaes, R., Ferreira, A., … de Bono, J. S. (2023). B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology, 83(3), 224–238. https://doi.org/10.1016/j.eururo.2022.09.004

Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342

Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer. (2022). Cellular Physiology and Biochemistry, 56(S4), 1–15. https://doi.org/10.33594/000000592

Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048

Han, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., Kumar, D., Caggiano, E. G., Capogiri, M., Zhang, B., Ji, Y., Maity, S. N., Hu, M., Bai, S., Aparicio, A. M., … Giancotti, F. G. (2022). Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 39(1), 110595. https://doi.org/10.1016/j.celrep.2022.110595

Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Alvarez Moreno, J. C., Polit, F., Lopez, O., Merhe, A., Abou-Kheir, W., Nieder, A. M., Poppiti, R., & Omarzai, Y. (2022). Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing. Medical Sciences, 10(1), 15. https://doi.org/10.3390/medsci10010015

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 28(1), 144–153. https://doi.org/10.1038/s41591-021-01600-6